{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:25:51Z","timestamp":1788801951135,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.amjmed.2021.06.015","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T04:22:12Z","timestamp":1626236532000},"page":"1218-1223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Peyronie Disease as a Marker of Inflammation\u2014Is There Hope on the Horizon?"],"prefix":"10.1016","volume":"134","author":[{"given":"Arthur L.M.","family":"Swislocki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2021.06.015_bib0001","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Penile curvature (Peyronie's disease). Available at: https:\/\/www.niddk.nih.gov\/health-information\/urologic-diseases\/penile-curvature-peyronies-disease. Accessed August 27, 2020."},{"key":"10.1016\/j.amjmed.2021.06.015_bib0002","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4103\/0970-1591.27633","article-title":"Peyronie's disease and erectile dysfunction: current understanding and future direction","volume":"22","author":"Levine","year":"2010","journal-title":"Indian J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0003","unstructured":"WhoNamedIt. Peyronie's disease. Available at: www.whonamedit.com. Accessed February 2020."},{"key":"10.1016\/j.amjmed.2021.06.015_bib0004","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1464-410X.1996.14120.x","article-title":"Francois de La Peyronie (1978-1747): the man and the disease he described","volume":"78","author":"Dunsmuir","year":"1996","journal-title":"Br J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0005","first-page":"123","article-title":"Early Dutch contributions on Peyronie's disease","volume":"31","author":"Haneveld","year":"1979","journal-title":"Arch Chir Neerl"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0006","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1557988314520951","article-title":"Peyronie's disease: a historical perspective","volume":"8","author":"Carriere","year":"2014","journal-title":"Am J Mens Health"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0007","unstructured":"American Urological Association. Peyronie's disease: AUA guideline. Available at: https:\/\/www.auanet.org\/guidelines\/peyronies-disease-guideline. Accessed November 5, 2020."},{"issue":"2","key":"10.1016\/j.amjmed.2021.06.015_bib0008","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ijir.3901518","article-title":"The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction","volume":"19","author":"Arafa","year":"2007","journal-title":"Int J Impot Res"},{"issue":"2","key":"10.1016\/j.amjmed.2021.06.015_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150157","article-title":"The prevalence of Peyronie's disease in the United States: a population-based study","volume":"11","author":"Stuntz","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.amjmed.2021.06.015_bib0010","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0011","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5534\/wjmh.180073","article-title":"The impact of clostridium histolyticum collagenase on the prevalence and management of Peyronie's disease in the United States","volume":"37","author":"Sun","year":"2019","journal-title":"World J Mens Health"},{"issue":"8","key":"10.1016\/j.amjmed.2021.06.015_bib0012","first-page":"61","article-title":"A review of the epidemiology and treatment of Peyronie's disease","author":"Ostrowski","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/282503","article-title":"A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States","volume":"2011","author":"Dibenedetti","year":"2011","journal-title":"Adv Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0014","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","article-title":"The prevalence of Peyronie's disease: results of a large survey","volume":"88","author":"Schwarzer","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1159\/000049830","article-title":"Peyronie's disease: prevalence and association with cigarette smoking: a multicenter population-based study in men aged 50-69 years","volume":"40","author":"La Pera","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0016","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1097\/01.ju.0000127744.18878.f1","article-title":"Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening","volume":"171","author":"Mulhall","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0017","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.ijir.3900727","article-title":"Prevalence of Peyronie's disease in men over 50-y-old from Southern Brazil","volume":"13","author":"Rhoden","year":"2001","journal-title":"Int J Impotence Res"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0018","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.euf.2019.08.006","article-title":"Erectile dysfunction and Peyronie's disease: genetic diseases?","volume":"6","author":"Patel","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0019","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tau.2016.04.05","article-title":"Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up","volume":"5","author":"Al-Thakafi","year":"2016","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0020","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jsxm.2018.04.640","article-title":"Increased risk of incident disease in men with Peyronie's disease: analysis of U.S. claims data","volume":"15","author":"Pastuszak","year":"2018","journal-title":"J Sex Med"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0021","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/j.1743-6109.2012.02704.x","article-title":"WNT2 locus is involved in genetic susceptibility of Peyronie's disease","volume":"9","author":"Dolmans","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0022","first-page":"713","article-title":"Multilayered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT\/\u03b2catenin signaling activation (Review)","volume":"42","author":"Katoh","year":"2018","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0023","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13018-018-0779-0","article-title":"Exposure to radial extracorporeal shock waves modulates viability and gene expression of human skeletal muscle cells: a controlled in vitro study","volume":"13","author":"Mattyasovszky","year":"2018","journal-title":"J Orthop Surg Res"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0024","first-page":"2000","article-title":"Radial extracorporeal shock wave therapy improves cerebral blood flow and neurological function in a rat model of cerebral ischemia","volume":"9","author":"Kang","year":"2017","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0025","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0026","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5152\/eurjrheum.2020.20101","article-title":"Is Peyronie's disease an IgG4-related disease?","volume":"8","author":"Solakhan","year":"2021","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0027","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.jsxm.2020.04.003","article-title":"Perspective regarding \"Is Peyronie's disease an IgG4-related disease\"","volume":"17","author":"Eisenberg","year":"2020","journal-title":"J Sex Med"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0028","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4653512","article-title":"Recent pathophysiological aspects of Peyronie's disease: role of free radicals, rationale, and therapeutic implications for antioxidant treatment-literature review","volume":"2017","author":"Paulis","year":"2017","journal-title":"Adv Urol."},{"key":"10.1016\/j.amjmed.2021.06.015_bib0029","first-page":"403","article-title":"Increased risk of cancer in men with Peyronie's Disease: A Cohort Study using a large United States insurance claims database","volume":"7","author":"Pastuszak","year":"2019","journal-title":"J Med"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00345-019-02815-6","article-title":"A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie's disease","volume":"38","author":"Patel","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0031","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4103\/UA.UA_164_18","article-title":"Peyronie's disease is common in poorly controlled diabetics but is not associated with the metabolic syndrome","volume":"11","author":"Habous","year":"2019","journal-title":"Urol Ann"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0032","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1111\/j.1743-6109.2008.00947.x","article-title":"Systemic vascular endothelial dysfunction in Peyronie's disease","volume":"5","author":"Agrawal","year":"2008","journal-title":"J Sex Med"},{"issue":"5","key":"10.1016\/j.amjmed.2021.06.015_bib0033","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.ijir.3900872","article-title":"Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie's disease","volume":"14","author":"Bivalacqua","year":"2002","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0034","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/dc14-2989","article-title":"Sclerostin and insulin resistance in prediabetes: evidence of a cross talk between bone and glucose metabolism","volume":"38","author":"Daniele","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0035","first-page":"152","article-title":"Roles of circulating WNT-signaling proteins and WNT-inhibitors in human adiposity, insulin resistance, insulin secretion, and inflammation","volume":"47","author":"Almario","year":"2015","journal-title":"Horm Metab Res"},{"issue":"1","key":"10.1016\/j.amjmed.2021.06.015_bib0036","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.maturitas.2010.01.009","article-title":"Testosterone and the aging male: to treat or not to treat?","volume":"66","author":"Bain","year":"2010","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.amjmed.2021.06.015_bib0037","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2164\/jandrol.111.012948","article-title":"Association between Peyronie disease and low serum testosterone levels: detection and therapeutic considerations","volume":"33","author":"Cavallini","year":"2012","journal-title":"J Androl"},{"issue":"3","key":"10.1016\/j.amjmed.2021.06.015_bib0038","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/jsm.12805","article-title":"Low testosterone has a similar prevalence among men with sexual dysfunction due to either Peyronie's disease or erectile dysfunction and does not correlate with Peyronie's disease severity","volume":"12","author":"Kirby","year":"2015","journal-title":"J Sex Med"},{"issue":"8","key":"10.1016\/j.amjmed.2021.06.015_bib0039","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jsxm.2019.05.021","article-title":"Testosterone levels are not associated with magnitude of deformity in men with Peyronie's disease","volume":"16","author":"Mulhall","year":"2019","journal-title":"J Sex Med"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0040","doi-asserted-by":"crossref","unstructured":"Candela L, Boeri L, Capogrosso P, et al. Serum testosterone levels are not associated with the severity of penile curvature in men with Peyronie's disease-findings from a cross-sectional study [e-pub ahead of print]. Int J Impot Res. doi: 10.1038\/s41443-020-0340-7, accessed month day, year.","DOI":"10.1038\/s41443-020-0340-7"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0041","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3389\/fimmu.2018.00794","article-title":"Androgen-induced immunosuppression","volume":"9","author":"Bupp","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.amjmed.2021.06.015_bib0042","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1073\/pnas.1321060111","article-title":"Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination","volume":"111","author":"Furman","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0043","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-019-0124-6","article-title":"Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females","volume":"4","author":"Potluri","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.amjmed.2021.06.015_bib0044","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/acel.12326","article-title":"How sex and age affect immune responses, susceptibility to infections, and response to vaccination","volume":"14","author":"Giefing-Kr\u00f6ll","year":"2015","journal-title":"Aging Cell"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0046","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.yhbeh.2016.11.009","article-title":"Testosterone and immune-reproductive tradeoffs in healthy women","volume":"88","author":"Lorenz","year":"2017","journal-title":"Horm Behav."},{"issue":"16","key":"10.1016\/j.amjmed.2021.06.015_bib0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12958-018-0431-1","article-title":"Radiations and male fertility","author":"Kesari","year":"2018","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0047","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00420-015-1049-7","article-title":"Effects of electromagnetic fields exposure on plasma hormonal and inflammatory pathway biomarkers in male workers of a power plant","volume":"89","author":"Wang","year":"2016","journal-title":"Int Arch Occup Environ Health"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0048","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/01.ju.0000070860.78370.08","article-title":"Radiation increases fibrogenic cytokine expression by Peyronie's disease fibroblasts","volume":"170","author":"Mulhall","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0049","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.envres.2018.09.015","article-title":"Real-world cell phone radiofrequency electromagnetic field exposures","volume":"171","author":"Wall","year":"2019","journal-title":"Environ Res"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3389\/fpubh.2019.00223","article-title":"Risks to health and well-being from radio-frequency radiation emitted by cell phones and other wireless devices","volume":"7","author":"Miller","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0051","first-page":"970","article-title":"The semen quality of the mobile phone users","volume":"36","author":"Rago","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0052","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.envint.2016.02.028","article-title":"Effects of cell phone use on semen parameters: results from the MARHCS cohort study in Chongqing","volume":"91","author":"Zhang","year":"2016","journal-title":"China Environ Int."},{"key":"10.1016\/j.amjmed.2021.06.015_bib0053","unstructured":"PriusChat. How much radiation in a key fob? Available at: https:\/\/priuschat.com\/threads\/smart-key-health-hazard. Accessed February 20, 2020."},{"issue":"4 Pt 1","key":"10.1016\/j.amjmed.2021.06.015_bib0054","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","article-title":"Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study","volume":"178","author":"Safarinejad","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0055","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","article-title":"Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study","volume":"16","author":"Safarinejad","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0056","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1464-410X.2003.04134.x","article-title":"Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease","volume":"91","author":"Prieto Castro","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0057","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.eururo.2006.10.042","article-title":"Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease","volume":"51","author":"Russell","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0058","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1464-410X.1975.tb03951.x","article-title":"Treatment of Peyronie's disease with procarbazine","volume":"47","author":"Oosterlinck","year":"1975","journal-title":"Br J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0059","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/j.1743-6109.2009.01235.x","article-title":"Efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: a prospective, randomized, double-blind placebo-controlled study [Retracted by Editor]","volume":"6","author":"Safarinejad","year":"2009","journal-title":"J Sex Med."},{"key":"10.1016\/j.amjmed.2021.06.015_bib0060","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","article-title":"Peyronie's disease study group of andrological group of German urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study","volume":"47","author":"Weidner","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0061","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ijir.2010.20","article-title":"Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study","volume":"22","author":"Safarinejad","year":"2010","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0062","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/aja.2010.117","article-title":"Pentoxifylline treatment and penile calcifications in men with Peyronie's disease","volume":"13","author":"Smith","year":"2011","journal-title":"Asian J Androl"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0063","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","article-title":"Experience with intraplaque injection of verapamil for Peyronie's disease","volume":"168","author":"Levine","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0064","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.juro.2013.05.022","article-title":"Outcomes of intralesional interferon-\u03b12B for the treatment of Peyronie disease","volume":"190","author":"Trost","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0066","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1056\/NEJMoa0810866","article-title":"CORD I Study Group. Injectable collagenase clostridium histolyticum for Dupuytren's contracture","volume":"361","author":"Hurst","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0067","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.juro.2015.03.092","article-title":"The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie's disease","volume":"194","author":"Yafi","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0068","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41443-019-0113-3","article-title":"Cellular signaling pathways modulated by low-intensity extracorporeal shock wave therapy","volume":"31","author":"Liu","year":"2019","journal-title":"Int J Impot Res"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2021.06.015_bib0069","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.21037\/tau.2017.12.03","article-title":"The extra-tunical grafting procedure for Peyronie's disease hourglass and indent deformities","volume":"7","author":"Reed-Maldonado","year":"2018","journal-title":"Transl Androl Urol"},{"issue":"7","key":"10.1016\/j.amjmed.2021.06.015_bib0071","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.esxm.2018.11.002","article-title":"Combined plaque incision, buccal mucosa grafting, and additional tunica albuginea plication for Peyronie's disease","author":"Cormio","year":"2019","journal-title":"Sex Med."},{"key":"10.1016\/j.amjmed.2021.06.015_bib0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/smrj.42","article-title":"Long-term results of reconstructive surgery for Peyronie's disease","volume":"3","author":"Garaffa","year":"2015","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0072","series-title":"Surgery: Its Theory and Practice","first-page":"1037","article-title":"Sores on the penis","author":"Walsham","year":"1903"},{"key":"10.1016\/j.amjmed.2021.06.015_bib0073","unstructured":"Bulik BS. Endo, building on DTC success, ramps up awareness campaign for Peyronie's disease. Available at: https:\/\/www.fiercepharma.com\/pharma\/building-dtc-success-endo-ramps-up-awareness-campaign-for-peyronie-s-disease. Accessed August 22, 2020."},{"issue":"Suppl 2","key":"10.1016\/j.amjmed.2021.06.015_bib0074","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.21037\/tau.2019.09.29","article-title":"A review of the evolving landscape between the consumer Internet and men's health","volume":"9","author":"Balasubramanian","year":"2020","journal-title":"Transl Androl Urol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934321004198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934321004198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:29:46Z","timestamp":1762079386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934321004198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":74,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0002934321004198"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2021.06.015","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peyronie Disease as a Marker of Inflammation\u2014Is There Hope on the Horizon?","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2021.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}